Tagged with Michael Good

Griffith University researchers have developed a new vaccine in pre-clinical studies to treat human babesiosis, a tick-transmitted disease closely related to malaria.

Using convalescent plasma, Griffith University researchers have identified how it may be possible to make a future vaccine that will provide protection against all major strains of COVID-19

Griffith University Institute for Glycomics researchers are closer to the development of a new vaccine aimed at preventing the deadly Streptococcus A (Strep A), which kills more than 500,000 people globally per year.

Partial immunity to SARS-CoV-2 combined with social distancing would significantly reduce mortality rates new mathematical modelling shows.

Bendigo Bank Paradise Point Community Bank Branch, long-standing supporters of Griffith University’s Institute for Glycomics, have donated $10,000 in funding towards the Institute’s vital COVID-19 research, aiding their fight against the global pandemic. Four teams of expert scientists from the Institute for Glycomics are targeting SARS-CoV-2, the virus that causes COVID-19, to discover new vaccines […]

Australian research into the use of convalescent plasma in clinical trials for the prevention and treatment of COVID-19 should be supported according to a leading immunologist.

Strep A, which can lead to serious illness and death if untreated, should be recognised as a Neglected Tropical Disease according to a leading infectious disease expert. Professor Michael Good AO, Principal Research Leader at Griffith University’s Institute for Glycomics, authored a paper published this week in PLOS Neglected Tropical Diseases. Neglected tropical diseases (NTDs) […]